Venus Remedies has launched for the first time a nanotechnology-based ready-to-use single vial Docetaxel in India under the brand name Taxedol. Taxedol (Docetaxel) is a single unit stable, pharmaceutical formulation which has lesser impurities in comparison to innovator product. According to a company press release, this one vial formulation of Docetaxel will not only make the administration of the drug easier by introducing the premix solution but at the same time will provide enhanced safety to patients and para-medical staff. Furthermore, the nano-scale size of the formulation results in improved penetration, higher efficacy, improved safety and lesser side effects.
A semi-synthetic cytostatic taxane analogue, Docetaxel is considered as one of the most effective and successful oncology products, which is used mainly for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer. The formulation consists of Docetaxel in nano particle form which gives 11 per cent higher cancer cell killing potential as compared to existing Docetaxel.
Dr Mufti Suhail Sayeed, VP-VMRC, Venus Remedies says, “This ready to use single vial formulation available in three strengths 20mg/0.5 ml, 80mg/2 ml and 120mg/3ml. We have received a positive response from the medical fraternity especially for the 120 mg strength as it is convenient not only for the medical staff but also for the patient.”
“Taxedol will not only weed out the competition from other players in the market but is hopeful of capturing significant share in Rs 1, 500 crore Indian cancer drug industry, which is speculated to show a steady growth over the coming few years,” said Dheeraj Aggarwal, CFO, Venus Remedies.
Besides this, the company is marketing Docetaxel under the brand name ‘DOXOL’ in the various emerging markets of Africa, Asia, CIS and LAC. Recently, the grant of European Market Authorisation for Portugal for Docetaxel has further opened up new grounds for Venus Remedies to cater to the EU market. The company is also present in the oncology segment in Europe and ROW through its wide product range, which includes Bortezomib, Pemeterxed, Paclitaxel and Gemcitabine among others.
EP News Bureau – Mumbai